As IMiDs are well-known to target IRF4 and MYC, our findings also suggest that the combination of IMiDs with DNMTi/HDACi combo treatment could be of therapeutic interest for high-risk MM patients. This evidence concerns the gene MYC and Miyoshi myopathy.